Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against

Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S11-5. doi: 10.1016/S1040-8428(10)70005-6.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Marrow Neoplasms / drug therapy*
  • Bone Marrow Neoplasms / secondary
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Clodronic Acid / administration & dosage
  • Clodronic Acid / therapeutic use
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / therapeutic use
  • Zoledronic Acid

Substances

  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Clodronic Acid
  • Zoledronic Acid